BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. J King Saud Univ Sci 2020;32:2845-53. [PMID: 32837113 DOI: 10.1016/j.jksus.2020.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Vivek-Ananth RP, Sahoo AK, Srivastava A, Samal A. Virtual screening of phytochemicals from Indian medicinal plants against the endonuclease domain of SFTS virus L polymerase. RSC Adv 2022;12:6234-47. [PMID: 35424542 DOI: 10.1039/d1ra06702h] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Md Nayeem S, Sohail EM, Srihari NV, Indira P, Srinivasa Reddy M. Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs. J Biomol Struct Dyn 2021;:1-8. [PMID: 33988066 DOI: 10.1080/07391102.2021.1924262] [Reference Citation Analysis]
3 Naidu SAG, Tripathi YB, Shree P, Clemens RA, Naidu AS. Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (Mpro) Autocleavage Enzyme Critical for COVID-19 Pathogenesis. J Diet Suppl 2021;:1-28. [PMID: 34821532 DOI: 10.1080/19390211.2021.2006388] [Reference Citation Analysis]
4 Españo E, Kim D, Kim J, Park SK, Kim JK. COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Netw 2021;21:e7. [PMID: 33728100 DOI: 10.4110/in.2021.21.e7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vergoten G, Bailly C. In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CLpro) and SARS-CoV-2 (Mpro). In Silico Pharmacol 2021;9:41. [PMID: 34230874 DOI: 10.1007/s40203-021-00101-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Adhikari N, Banerjee S, Baidya SK, Ghosh B, Jha T. Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences. J Mol Struct 2021;:132041. [PMID: 34866654 DOI: 10.1016/j.molstruc.2021.132041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Pandey A, Sharma M. Reappraisal of trifluperidol against Nsp3 as a potential therapeutic for novel COVID-19: a molecular docking and dynamics study. Future Virol 2021. [PMID: 34290823 DOI: 10.2217/fvl-2020-0361] [Reference Citation Analysis]
8 Gonzalez BL, de Oliveira NC, Ritter MR, Tonin FS, Melo EB, Sanches ACC, Fernandez-Llimos F, Petruco MV, de Mello JCP, Chierrito D, de Medeiros Araújo DC. The naturally-derived alkaloids as a potential treatment for COVID-19: A scoping review. Phytother Res 2022. [PMID: 35355337 DOI: 10.1002/ptr.7442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ameen F, Mamidala E, Davella R, Vallala S. Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. J Infect Public Health 2021:S1876-0341(21)00199-4. [PMID: 34326009 DOI: 10.1016/j.jiph.2021.07.012] [Reference Citation Analysis]
10 Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K, Sami H. Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules. Saudi J Biol Sci 2021. [PMID: 34548836 DOI: 10.1016/j.sjbs.2021.09.042] [Reference Citation Analysis]
11 Waman VP, Sen N, Varadi M, Daina A, Wodak SJ, Zoete V, Velankar S, Orengo C. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Brief Bioinform 2021;22:742-68. [PMID: 33348379 DOI: 10.1093/bib/bbaa362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
12 Llanos MA, Gantner ME, Rodriguez S, Alberca LN, Bellera CL, Talevi A, Gavernet L. Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study. J Chem Inf Model 2021;61:3758-70. [PMID: 34313128 DOI: 10.1021/acs.jcim.1c00404] [Reference Citation Analysis]
13 Majnooni MB, Fakhri S, Bahrami G, Naseri M, Farzaei MH, Echeverría J. Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms. Evid Based Complement Alternat Med 2021;2021:6632623. [PMID: 34104202 DOI: 10.1155/2021/6632623] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gammeltoft KA, Zhou Y, Duarte Hernandez CR, Galli A, Offersgaard A, Costa R, Pham LV, Fahnøe U, Feng S, Scheel TKH, Ramirez S, Bukh J, Gottwein JM. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrob Agents Chemother 2021;65:e0268020. [PMID: 34097489 DOI: 10.1128/AAC.02680-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Takahashi JA, Barbosa BVR, Lima MTNS, Cardoso PG, Contigli C, Pimenta LPS. Antiviral fungal metabolites and some insights into their contribution to the current COVID-19 pandemic. Bioorg Med Chem 2021;46:116366. [PMID: 34438338 DOI: 10.1016/j.bmc.2021.116366] [Reference Citation Analysis]
16 Al-Ansari MM, Sahlah SA, AlHumaid L, Ranjit Singh AJ. Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review. J King Saud Univ Sci 2021;33:101286. [PMID: 33519144 DOI: 10.1016/j.jksus.2020.101286] [Reference Citation Analysis]
17 Novak J, Potemkin VA. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Mol Divers 2022. [PMID: 35001230 DOI: 10.1007/s11030-021-10355-8] [Reference Citation Analysis]
18 Ali F, Alom S, Shakya A, Ghosh SK, Singh UP, Bhat HR. Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2. Arch Pharm (Weinheim) 2022;:e2100360. [PMID: 35244237 DOI: 10.1002/ardp.202100360] [Reference Citation Analysis]
19 Azad I, Khan T, Maurya AK, Irfan Azad M, Mishra N, Alanazi AM. Identification of Severe Acute Respiratory Syndrome Coronavirus-2 inhibitors through in silico structure-based virtual screening and molecular interaction studies. J Mol Recognit 2021;34:e2918. [PMID: 34132436 DOI: 10.1002/jmr.2918] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Mitra S, Prova SR, Sultana SA, Das R, Nainu F, Emran TB, Tareq AM, Uddin MS, Alqahtani AM, Dhama K, Simal-Gandara J. Therapeutic potential of indole alkaloids in respiratory diseases: A comprehensive review. Phytomedicine 2021;90:153649. [PMID: 34325978 DOI: 10.1016/j.phymed.2021.153649] [Reference Citation Analysis]
21 Fakhri S, Piri S, Majnooni MB, Farzaei MH, Echeverría J. Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach. Front Pharmacol 2020;11:621099. [PMID: 33708124 DOI: 10.3389/fphar.2020.621099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Negru PA, Miculas DC, Behl T, Bungau AF, Marin R, Bungau SG. Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses. Biomedicine & Pharmacotherapy 2022;153:113432. [DOI: 10.1016/j.biopha.2022.113432] [Reference Citation Analysis]